Alfonsa Claudia Taiello

Alfonsa Claudia Taiello

Auto-generated profile, based on publicly available information

Alfonsa Claudia Taiello

Dipartimento di Neurologia, Centro Regionale SLA, AOUP 'P Giaccone', Università di Palermo, Palermo, Italy

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 February 2015 in European Journal of Neurology
Verified
Journal Article
Open access
PDF file
AEAntonio Emanuele Elia
Antonio Emanuele Elia
SLS. Lalli
S. Lalli
MMM. R. Monsurrò
M. R. Monsurrò
ASA. Sagnelli
A. Sagnelli
ATA. C. Taiello
A. C. Taiello
AAA. Albanese
A. Albanese
Background and purpose: Tauroursodeoxycholic acid (TUDCA) is a hydrophilic bile acid that is produced in the liver and used for treatment of chronic cholestatic liver diseases. Experimental studies suggest that TUDCA may have cytoprotective and anti‐apoptotic action, with potential neuroprotective activity. A proof of principle approach was adopted to provide preliminary data regarding the efficacy and tolerability of TUDCA in a series of patients with amyotrophic lateral sclerosis (ALS).Methods: As a proof of principle, using a double‐blind placebo controlled design, 34 ALS patients under treatment with riluzole who were randomized to placebo or TUDCA (1 g twice daily for 54 weeks) were evaluated after a lead‐in period of 3 months. The patients were examined every 6 weeks. The primary outcome was the proportion of responders [those subjects with improvement of at least 15% in the Amyotrophic Lateral Sclerosis Functional Rating Scale Revised (ALSFRS‐R) slope during the treatment period compared to the lead‐in phase]. Secondary outcomes included between‐treatment comparison of ALSFRS‐R at study end, comparison of the linear regression slopes for ALSFFRS‐R mean scores and the occurrence of adverse events.Results: Tauroursodeoxycholic acid was well tolerated; there were no between‐group differences for adverse events. The proportion of responders was higher under TUDCA (87%) than under placebo (P = 0.021; 43%). At study end baseline‐adjusted ALSFRS‐R was significantly higher (P = 0.007) in TUDCA than in placebo groups. Comparison of the slopes of regression analysis showed slower progression in the TUDCA than in the placebo group (P < 0.01).Conclusions: This pilot study provides preliminary clinical data indicating that TUDCA is safe and may be effective in ALS.

1 July 2012 in Clinical Neurology and Neurosurgery
Verified
Journal Article
Closed access
ECEleonora Cellura
Eleonora Cellura
RSRossella Spataro
Rossella Spataro
ATAlfonsa Claudia Taiello
Alfonsa Claudia Taiello
VBVincenzo La Bella
Vincenzo La Bella

8 May 2012 in Amyotrophic Lateral Sclerosis
Verified
Journal Article
Closed access
Paolo RagonesePaolo Ragonese
Paolo Ragonese
ECEleonora Cellura
Eleonora Cellura
PAPaolo Aridon
Paolo Aridon
MDMarco D'Amelio
Marco D'Amelio
RSRossella Spataro
Rossella Spataro
GSGiovanni Savettieri
Giovanni Savettieri
Our objective was to investigate incidence of amyotrophic lateral sclerosis (ALS) in Sicily, southern Italy, by means of a population based study. We included people with ALS resident in five Sicilian provinces, whose onset occurred in the two-year period 2005−2006 (population at 31 December 2006: 3,481,096 inhabitants). A multisource case-finding procedure was adopted and patients were classified as affected by ALS according to revised El Escorial criteria. During the two-year surveillance period, 97 patients meeting eligibility criteria included 57 males (58.8%) and 40 females (41.2%). Crude annual incidence rate was 1.4/100,000 person years (95% CI 1.33−1.47). The incidence rate was higher in males (1.71/100,000; CI 1.61−1.81) than in females (1.11/100,000; CI 1.01−1.21). Standardized incidence rate for the total population in the 45−74-years-old age group was 3.22 (CI 3.11−3.33). Prevalence rate was 6.0/100,000 (CI 5.97−6.03), higher in males (7.1/100,000; CI 7.02−7.18) than females (4.9/100,000; CI 4.86−4.94). In conclusion, ALS rates observed in the present study are higher in males than females, with a peak of incidence at 70 years of age in both genders. These findings are consistent with those of other population based European studies.

1 March 2013 in Journal of the Neurological Sciences
Verified
Journal Article
Closed access
CMConcetta Manno
Concetta Manno
ALAlessio Lipari
Alessio Lipari
VBValeria Bono
Valeria Bono
ATAlfonsa Claudia Taiello
Alfonsa Claudia Taiello
VBVincenzo La Bella
Vincenzo La Bella

22 March 2018 in European Neurology
Verified
Journal Article
Closed access
PDF file
ATAlfonsa Claudia Taiello
Alfonsa Claudia Taiello
RSRossella Spataro
Rossella Spataro
VBVincenzo La Bella
Vincenzo La Bella
Background and Purpose: The palmomental reflex (PMR) is a primitive reflex that might be released due to inhibition in adulthood. It has been associated with several neurodegenerative conditions. The aim of the present study was to evaluate the frequency of PMR in amyotrophic lateral sclerosis (ALS). Patients and Methods: Non-demented ALS patients (n = 179) were recruited. Two groups of disease controls were enrolled: (a) non-demented patients with other neurological disorders (NC; n = 86, mean age 60 ± 14 years); (b) healthy subjects, healthy controls (HC; n = 175, mean age 61 ± 12 years). PMR was elicited by a brisk stroke along the thenar eminence of the right hand with a key or a pen. Results: The PMR could be elicited in 46% of the ALS patients, compared to 29% of NC and 16% of HC (p < 0.001). A multivariate analysis showed that bulbar-onset and female gender are associated with an increased risk of PMR. Conclusion: We demonstrate a higher frequency of the PMR in ALS patients compared to NC or HC. Its expression increases with age, being higher in bulbar-onset patients. Given that the reflex circuit is located in the brain stem, its release due to inhibition might be associated to the presence of a cortico-bulbar tract dysfunction in ALS.